

BODISEN BIOTECH, INC

Form 3

March 30, 2006

**FORM 3 UNITED STATES SECURITIES AND EXCHANGE COMMISSION****Washington, D.C. 20549**

OMB APPROVAL

OMB  
Number: 3235-0104Expires: January 31,  
2005Estimated average  
burden hours per  
response... 0.5**INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF  
SECURITIES**

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934,  
Section 17(a) of the Public Utility Holding Company Act of 1935 or Section  
30(h) of the Investment Company Act of 1940

(Print or Type Responses)

1. Name and Address of Reporting  
Person \*

McManus Patrick

(Last) (First) (Middle)

2. Date of Event Requiring  
Statement

(Month/Day/Year)

08/25/2005

3. Issuer Name **and** Ticker or Trading Symbol  
BODISEN BIOTECH, INC [BBC]4. Relationship of Reporting  
Person(s) to Issuer5. If Amendment, Date Original  
Filed(Month/Day/Year)

(Check all applicable)

☒ Director ☐ 10% Owner  
☐ Officer ☐ Other  
(give title below) (specify below)

6. Individual or Joint/Group  
Filing(Check Applicable Line)  
☒ Form filed by One Reporting  
Person  
☐ Form filed by More than One  
Reporting Person

17 BALTIMORE ST

(Street)

LYNN, MA 01902

(City) (State) (Zip)

**Table I - Non-Derivative Securities Beneficially Owned**1. Title of Security  
(Instr. 4)2. Amount of Securities  
Beneficially Owned  
(Instr. 4)

3. Ownership  
Form:  
Direct (D)  
or Indirect  
(I)  
(Instr. 5)

4. Nature of Indirect Beneficial  
Ownership  
(Instr. 5)

Reminder: Report on a separate line for each class of securities beneficially  
owned directly or indirectly.

SEC 1473 (7-02)

**Persons who respond to the collection of  
information contained in this form are not  
required to respond unless the form displays a  
currently valid OMB control number.**

**Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)**1. Title of Derivative Security  
(Instr. 4)2. Date Exercisable and  
Expiration Date  
(Month/Day/Year)

Date Expiration  
Exercisable Date

3. Title and Amount of  
Securities Underlying  
Derivative Security  
(Instr. 4)

Title Amount or  
Number of  
Shares

4. Conversion  
or Exercise  
Price of  
Derivative  
Security

5. Ownership  
Form of  
Derivative  
Security:  
Direct (D)  
or Indirect  
(I)  
(Instr. 5)

6. Nature of Indirect  
Beneficial  
Ownership  
(Instr. 5)

# Edgar Filing: BODISEN BIOTECH, INC - Form 3

stock options	06/04/2004	06/04/2009	common stock	50,000 <sup>(1)</sup>	\$ 5	D	Â
stock options	12/28/2004	12/28/2009	common stock	5,000 <sup>(2)</sup>	\$ 5.8	D	Â
stock options	10/04/2005	10/04/2010	common stock	13,000 <sup>(3)</sup>	\$ 6.72	D	Â

## Reporting Owners

Reporting Owner Name / Address	Relationships			
	Director	10% Owner	Officer	Other
McManus Patrick 17 BALTIMORE ST LYNN, MA 01902	Â X	Â	Â	Â

## Signatures

/s/ Patrick  
McManus 03/29/2006

Signature of  
Reporting Person

Date

## Explanation of Responses:

- \* If the form is filed by more than one reporting person, *see* Instruction 5(b)(v).
- \*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations. *See* 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
- (1) Pursuant to the 2004 Stock Option Plan, 25,000 options vested immediately, and the remainder 25,000 options vested over 8 quarterly installments.
- (2) Pursuant to the 2004 Stock Option Plan the 5,000 option vested on December 31, 2004.
- (3) Pursuant to the 2004 Stock Option Plan, 10,000 options vested immediately, and the remainder 3,000 options vested over the next three months.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, *See* Instruction 6 for procedure.  
Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.